10.01.04
Sytrinol™, the proprietary cardiovascular wellness compound from SourceOne Global Partners, will be the subject of a phase III clinical trial. This study is designed as a double-blind, crossover, randomized trial of 120 moderately hypercholesterolemic men and women who are divided into two groups of 60 each. They will consume either a dosage of 150 mg Sytrinol or placebo twice daily for 12 weeks.